CD19 and lymphoma: For example, anti-CD19 CAR-NK cells obtained from iPSC engineered to express high affinity non-cleavable CD16 have demonstrated potent anti-lymphoma efficacy in murine models and were able to target both CD19- and CD19+ target cells in combination with anti-CD20 antibodies [66].